Loading
Fate Therapeutics
Fate Therapeutics builds iPSC-derived off-the-shelf CAR-T and CAR-NK cells (FT819, FT522) for cancer and autoimmune disease.
Overview
Fate Therapeutics, based in San Diego and listed as FATE, builds off-the-shelf CAR-T and CAR-NK cells derived from induced pluripotent stem cells, including FT819 and FT522, for cancer and autoimmune disease. FT819 is a clonal iPSC-derived CD19 CAR-T, FT522 is a CD19 CAR-NK with alloimmune defence receptors designed to avoid conditioning chemotherapy, the company presented at ASCO and EULAR 2026, and it has a solid-tumour collaboration with Ono. OnCo links it to diffuse large B-cell lymphoma, to allogeneic cell therapy, CAR-NK and CAR-T, to CD19 as a target and to ideas on qualifying one iPSC master cell bank for many products. Manufacturing cost and time for living medicines is the bottleneck iPSC-derived cells are meant to relieve. Whether iPSC-derived cells persist and perform as well as patient-derived ones is the open question.
Connected
11Similar pages
- CompanyCaribou Biosciences
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19.
- CompanySana Biotechnology
Shares Qualify one iPSC master cell bank once for many off-the-shelf cell products, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19.
- CompanyCentury Therapeutics
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
- CompanyNkarta
Shares Off-the-shelf natural killer cells to sweep up residual disease, CAR-NK & CAR-macrophage, CD19, Diffuse large B-cell lymphoma.
- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- PersonKatayoun Rezvani
Shares CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, CD19, Diffuse large B-cell lymphoma.
- CompanyCellogen Therapeutics
Shares Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- CompanyAllogene Therapeutics
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19.
cancers
fronts
technologies
targets
institutions
ideas
bottlenecks
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
fatetherapeutics.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/